ft 11 aug 93 lex column uk pharmaceut outcom price negoti uk govern add great de rate pharmaceut sector uk account small proport sale oversea drug compani even glaxo expos domest industri might view 2 5 per cent annual price cut demand govern moder result return capit 17 21 per cent allow research develop expenditur uk formula better achiev industri real return look handsom inflat remain subdu question stock market though whether rate return adequ compens degre risk although slide pharmaceut share far reflect doubt return earn drug compani invest pharmaceut also becom riski big buyer healthcar longer prepar pay high price drug offer margin improv cheaper altern uk govern blacklist product case point sale growth futur like come drug genuin breakthrough field whether stock market investor prepar nurs fewer blockbust compound research develop lower overal rate return open question